#USA #San Diego #Neurocrine Biosciences #Tardive Dyskinesia #NBI-1065890

Neurocrine Biosciences Advances Clinical Research with NBI-1065890

Neurocrine Biosciences, Inc., a prominent player in the biopharmaceutical field, has embarked on an exciting new Phase 2 clinical study to evaluate NBI-1065890 as a treatment for adults suffering from tardive dyskinesia (TD). This investigational compound represents a significant advancement in the ongoing effort to address movement disorders linked to certain medications used in mental health treatment.

Understanding the Importance of NBI-1065890

NBI-1065890 is a next-generation, selective inhibitor specifically targeting the vesicular monoamine transporter 2 (VMAT2). This unique compound has been meticulously developed by Neurocrine, leveraging nearly two decades of expertise in VMAT2 inhibition. The design of NBI-1065890 is aimed at offering a distinctive clinical profile, with the potential for longer-lasting treatment options for individuals diagnosed with TD. According to Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, "NBI-1065890 is an internally discovered molecule with unique characteristics that may allow for broader patient benefits in tardive dyskinesia therapy." The initiation of this Phase 2 clinical study is perceived as a step vital to shaping the future of VMAT2 biology and improving outcomes for affected patients.

Details of the Clinical Study

This trial will be a randomized, double-blind, placebo-controlled study aimed at enrolling around 100 adult participants diagnosed with tardive dyskinesia. It will rigorously assess the efficacy, safety, and tolerability of NBI-1065890 compared to a placebo group. The primary measure of effectiveness will involve observing changes from baseline in the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score after eight weeks of treatment.

Neurocrine's commitment to innovation is evident in its previous accomplishments, which include the successful development and FDA approval of valbenazine in 2017. This represented the first drug sanctioned for the treatment of tardive dyskinesia and further strengthened the company’s position in addressing movement disorders. In 2023, Neurocrine received FDA approval for valbenazine to treat chorea linked with Huntington's disease, reinforcing its dedication to tackling complex neurological conditions.

Tackling Tardive Dyskinesia

Tardive dyskinesia is characterized by involuntary movements and typically results from long-term use of certain antipsychotic medications, which act on dopamine receptors in the brain. Patients with TD often experience disruptive symptoms that can severely impair their quality of life. Current estimates suggest that around 800,000 adults in the United States live with this challenging disorder, underlining the need for more effective treatment strategies.

NBI-1065890 has shown promise due to its selective and potent mechanism as an orally bioavailable VMAT2 inhibitor, anticipated to provide therapeutic benefits not only for tardive dyskinesia but also for other hyperkinetic movement disorders and central nervous system conditions where dopaminergic signaling is disrupted.

About Neurocrine Biosciences

Neurocrine Biosciences has garnered recognition as a leader in the biopharmaceutical landscape, dedicated to relieving suffering through innovative treatment solutions. The company focuses on delivering life-changing therapies for individuals grappling with a wide array of neurological, psychiatric, endocrine, and immunological disorders. With an expanding portfolio that includes FDA-approved medications for various conditions alongside a robust development pipeline, Neurocrine continues to push the boundaries of neuroscience. The company has embraced the motto "You Deserve Brave Science" as it works tirelessly to discover and develop therapeutic options for conditions that have long been inadequately addressed.

For further information regarding the Phase 2 trial for NBI-1065890, stakeholders and interested parties are encouraged to visit ClinicalTrials.gov.

Conclusion

Neurocrine Biosciences’ launch of the Phase 2 clinical study for NBI-1065890 signifies a momentous stride toward addressing the plight of patients afflicted by tardive dyskinesia. As research progresses, there is hope that this investigational treatment could offer improved outcomes for those affected by this challenging movement disorder.